Readout and delayed transmission of initial afferent V1 activity in decisions about stimulus contrast

FierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series B

Endpoints News#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six months

Roche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical Executive

BioPharma DiveCity banks nearly $100M for next-gen RNAi drugs

Endpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi future

Clinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake Mice

Clinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use Disorders

Endpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicines

Clinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer Research

Clinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental Models

BioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drug

Clinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway